Neuropsychological performance in LRRK2 G2019S carriers with Parkinson's disease

Roy N. Alcalay, Helen Mejia-Santana, Anat Mirelman, Rachel Saunders-Pullman, Deborah Raymond, Christina Palmese, Elise Caccappolo, Laurie Ozelius, Avi Orr-Urtreger, Lorraine Clark, Nir Giladi, Susan Bressman, Karen Marder, Ming X. Tang, Helen Mejia Santana, Ernest Roos, Martha Orbe-Reilly, Stanley Fahn, Lucien Cote, Cheryl Waters & 37 others Pietro Mazzoni, Blair Ford, Elan Louis, Oren Levy, Llency Rosado, Diana Ruiz, Tsvyatko Dorovski, Paul Greene, Karen S. Marder, Tanya Gurevich, Anat Bar Shira, Mali GanaWeisz, Kira Yasinovsky, Maayan Zalis, Avner Thaler, Yaacov Balash, Shabtai Hertzel, Ziv Gan, Hila Kobo, Ariella Hillel, Anat Shkedy, Andres Deik, Matthew James Barrett, Jose Cabassa, Mark Groves, Ann L. Hunt, Naomi Lubarr, Marta San Luciano, Joan Miravite, Rivka Sachdev, Harini Sarva, Lawrence Severt, Vicki Shanker, Matthew Carrington Swan, Jeannie Soto-Valencia, Brooke Johannes, Robert Ortega

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background: Ashkenazi Jewish (AJ) LRRK2 carriers are more likely to manifest the postural instability gait difficulty (PIGD) motor phenotype than non-carriers but perform similarly to non-carriers on cognitive screening tests. Objective: To compare the cognitive profiles of AJ with Parkinson's disease (PD) with and without LRRK2 G2019S mutations using a comprehensive neuropsychological battery. Methods: We administered a neuropsychological battery to PD participants in the Michael J. Fox Foundation AJ consortium. Participants (n=236) from Beth Israel Medical Center, NY, Columbia University Medical Center, NY and Tel Aviv Medical Center, Israel included 116 LRRK2 G2019S carriers and 120 non-carriers. Glucocerbrosidase mutation carriers were excluded. We compared performance on each neuropsychological test between carriers and non-carriers. Participants in New York (n=112) were evaluated with the entire battery. Tel Aviv participants (n=124) were evaluated on attention, executive function and psychomotor speed tasks. The association between G2019S mutation status (predictor) and each neuropsychological test (outcome) was assessed using linear regression models adjusted for PIGD motor phenotype, site, sex, age, disease duration, education, Unified Parkinson's Disease Rating Scale (UPDRS) Part III, levodopa equivalent dose, and Geriatric Depression Score (GDS). Results: Carriers had longer disease duration (p

Original languageEnglish (US)
Pages (from-to)106-110
Number of pages5
JournalParkinsonism and Related Disorders
Volume21
Issue number2
DOIs
StatePublished - Feb 1 2015
Externally publishedYes

Fingerprint

Parkinson Disease
Neuropsychological Tests
Israel
Gait
Mutation
Linear Models
Phenotype
Executive Function
Levodopa
Geriatrics
Depression
Education

Keywords

  • Genetics
  • LRRK2
  • Neuropsychological tests
  • Parkinson

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Clinical Neurology
  • Neurology
  • Medicine(all)

Cite this

Alcalay, R. N., Mejia-Santana, H., Mirelman, A., Saunders-Pullman, R., Raymond, D., Palmese, C., ... Ortega, R. (2015). Neuropsychological performance in LRRK2 G2019S carriers with Parkinson's disease. Parkinsonism and Related Disorders, 21(2), 106-110. https://doi.org/10.1016/j.parkreldis.2014.09.033

Neuropsychological performance in LRRK2 G2019S carriers with Parkinson's disease. / Alcalay, Roy N.; Mejia-Santana, Helen; Mirelman, Anat; Saunders-Pullman, Rachel; Raymond, Deborah; Palmese, Christina; Caccappolo, Elise; Ozelius, Laurie; Orr-Urtreger, Avi; Clark, Lorraine; Giladi, Nir; Bressman, Susan; Marder, Karen; Tang, Ming X.; Santana, Helen Mejia; Roos, Ernest; Orbe-Reilly, Martha; Fahn, Stanley; Cote, Lucien; Waters, Cheryl; Mazzoni, Pietro; Ford, Blair; Louis, Elan; Levy, Oren; Rosado, Llency; Ruiz, Diana; Dorovski, Tsvyatko; Greene, Paul; Marder, Karen S.; Gurevich, Tanya; Shira, Anat Bar; GanaWeisz, Mali; Yasinovsky, Kira; Zalis, Maayan; Thaler, Avner; Balash, Yaacov; Hertzel, Shabtai; Gan, Ziv; Kobo, Hila; Hillel, Ariella; Shkedy, Anat; Deik, Andres; Barrett, Matthew James; Cabassa, Jose; Groves, Mark; Hunt, Ann L.; Lubarr, Naomi; Luciano, Marta San; Miravite, Joan; Sachdev, Rivka; Sarva, Harini; Severt, Lawrence; Shanker, Vicki; Swan, Matthew Carrington; Soto-Valencia, Jeannie; Johannes, Brooke; Ortega, Robert.

In: Parkinsonism and Related Disorders, Vol. 21, No. 2, 01.02.2015, p. 106-110.

Research output: Contribution to journalArticle

Alcalay, RN, Mejia-Santana, H, Mirelman, A, Saunders-Pullman, R, Raymond, D, Palmese, C, Caccappolo, E, Ozelius, L, Orr-Urtreger, A, Clark, L, Giladi, N, Bressman, S, Marder, K, Tang, MX, Santana, HM, Roos, E, Orbe-Reilly, M, Fahn, S, Cote, L, Waters, C, Mazzoni, P, Ford, B, Louis, E, Levy, O, Rosado, L, Ruiz, D, Dorovski, T, Greene, P, Marder, KS, Gurevich, T, Shira, AB, GanaWeisz, M, Yasinovsky, K, Zalis, M, Thaler, A, Balash, Y, Hertzel, S, Gan, Z, Kobo, H, Hillel, A, Shkedy, A, Deik, A, Barrett, MJ, Cabassa, J, Groves, M, Hunt, AL, Lubarr, N, Luciano, MS, Miravite, J, Sachdev, R, Sarva, H, Severt, L, Shanker, V, Swan, MC, Soto-Valencia, J, Johannes, B & Ortega, R 2015, 'Neuropsychological performance in LRRK2 G2019S carriers with Parkinson's disease', Parkinsonism and Related Disorders, vol. 21, no. 2, pp. 106-110. https://doi.org/10.1016/j.parkreldis.2014.09.033
Alcalay RN, Mejia-Santana H, Mirelman A, Saunders-Pullman R, Raymond D, Palmese C et al. Neuropsychological performance in LRRK2 G2019S carriers with Parkinson's disease. Parkinsonism and Related Disorders. 2015 Feb 1;21(2):106-110. https://doi.org/10.1016/j.parkreldis.2014.09.033
Alcalay, Roy N. ; Mejia-Santana, Helen ; Mirelman, Anat ; Saunders-Pullman, Rachel ; Raymond, Deborah ; Palmese, Christina ; Caccappolo, Elise ; Ozelius, Laurie ; Orr-Urtreger, Avi ; Clark, Lorraine ; Giladi, Nir ; Bressman, Susan ; Marder, Karen ; Tang, Ming X. ; Santana, Helen Mejia ; Roos, Ernest ; Orbe-Reilly, Martha ; Fahn, Stanley ; Cote, Lucien ; Waters, Cheryl ; Mazzoni, Pietro ; Ford, Blair ; Louis, Elan ; Levy, Oren ; Rosado, Llency ; Ruiz, Diana ; Dorovski, Tsvyatko ; Greene, Paul ; Marder, Karen S. ; Gurevich, Tanya ; Shira, Anat Bar ; GanaWeisz, Mali ; Yasinovsky, Kira ; Zalis, Maayan ; Thaler, Avner ; Balash, Yaacov ; Hertzel, Shabtai ; Gan, Ziv ; Kobo, Hila ; Hillel, Ariella ; Shkedy, Anat ; Deik, Andres ; Barrett, Matthew James ; Cabassa, Jose ; Groves, Mark ; Hunt, Ann L. ; Lubarr, Naomi ; Luciano, Marta San ; Miravite, Joan ; Sachdev, Rivka ; Sarva, Harini ; Severt, Lawrence ; Shanker, Vicki ; Swan, Matthew Carrington ; Soto-Valencia, Jeannie ; Johannes, Brooke ; Ortega, Robert. / Neuropsychological performance in LRRK2 G2019S carriers with Parkinson's disease. In: Parkinsonism and Related Disorders. 2015 ; Vol. 21, No. 2. pp. 106-110.
@article{6f264f9a5c234fa89a8fca40b069cd6b,
title = "Neuropsychological performance in LRRK2 G2019S carriers with Parkinson's disease",
abstract = "Background: Ashkenazi Jewish (AJ) LRRK2 carriers are more likely to manifest the postural instability gait difficulty (PIGD) motor phenotype than non-carriers but perform similarly to non-carriers on cognitive screening tests. Objective: To compare the cognitive profiles of AJ with Parkinson's disease (PD) with and without LRRK2 G2019S mutations using a comprehensive neuropsychological battery. Methods: We administered a neuropsychological battery to PD participants in the Michael J. Fox Foundation AJ consortium. Participants (n=236) from Beth Israel Medical Center, NY, Columbia University Medical Center, NY and Tel Aviv Medical Center, Israel included 116 LRRK2 G2019S carriers and 120 non-carriers. Glucocerbrosidase mutation carriers were excluded. We compared performance on each neuropsychological test between carriers and non-carriers. Participants in New York (n=112) were evaluated with the entire battery. Tel Aviv participants (n=124) were evaluated on attention, executive function and psychomotor speed tasks. The association between G2019S mutation status (predictor) and each neuropsychological test (outcome) was assessed using linear regression models adjusted for PIGD motor phenotype, site, sex, age, disease duration, education, Unified Parkinson's Disease Rating Scale (UPDRS) Part III, levodopa equivalent dose, and Geriatric Depression Score (GDS). Results: Carriers had longer disease duration (p",
keywords = "Genetics, LRRK2, Neuropsychological tests, Parkinson",
author = "Alcalay, {Roy N.} and Helen Mejia-Santana and Anat Mirelman and Rachel Saunders-Pullman and Deborah Raymond and Christina Palmese and Elise Caccappolo and Laurie Ozelius and Avi Orr-Urtreger and Lorraine Clark and Nir Giladi and Susan Bressman and Karen Marder and Tang, {Ming X.} and Santana, {Helen Mejia} and Ernest Roos and Martha Orbe-Reilly and Stanley Fahn and Lucien Cote and Cheryl Waters and Pietro Mazzoni and Blair Ford and Elan Louis and Oren Levy and Llency Rosado and Diana Ruiz and Tsvyatko Dorovski and Paul Greene and Marder, {Karen S.} and Tanya Gurevich and Shira, {Anat Bar} and Mali GanaWeisz and Kira Yasinovsky and Maayan Zalis and Avner Thaler and Yaacov Balash and Shabtai Hertzel and Ziv Gan and Hila Kobo and Ariella Hillel and Anat Shkedy and Andres Deik and Barrett, {Matthew James} and Jose Cabassa and Mark Groves and Hunt, {Ann L.} and Naomi Lubarr and Luciano, {Marta San} and Joan Miravite and Rivka Sachdev and Harini Sarva and Lawrence Severt and Vicki Shanker and Swan, {Matthew Carrington} and Jeannie Soto-Valencia and Brooke Johannes and Robert Ortega",
year = "2015",
month = "2",
day = "1",
doi = "10.1016/j.parkreldis.2014.09.033",
language = "English (US)",
volume = "21",
pages = "106--110",
journal = "Parkinsonism and Related Disorders",
issn = "1353-8020",
publisher = "Elsevier BV",
number = "2",

}

TY - JOUR

T1 - Neuropsychological performance in LRRK2 G2019S carriers with Parkinson's disease

AU - Alcalay, Roy N.

AU - Mejia-Santana, Helen

AU - Mirelman, Anat

AU - Saunders-Pullman, Rachel

AU - Raymond, Deborah

AU - Palmese, Christina

AU - Caccappolo, Elise

AU - Ozelius, Laurie

AU - Orr-Urtreger, Avi

AU - Clark, Lorraine

AU - Giladi, Nir

AU - Bressman, Susan

AU - Marder, Karen

AU - Tang, Ming X.

AU - Santana, Helen Mejia

AU - Roos, Ernest

AU - Orbe-Reilly, Martha

AU - Fahn, Stanley

AU - Cote, Lucien

AU - Waters, Cheryl

AU - Mazzoni, Pietro

AU - Ford, Blair

AU - Louis, Elan

AU - Levy, Oren

AU - Rosado, Llency

AU - Ruiz, Diana

AU - Dorovski, Tsvyatko

AU - Greene, Paul

AU - Marder, Karen S.

AU - Gurevich, Tanya

AU - Shira, Anat Bar

AU - GanaWeisz, Mali

AU - Yasinovsky, Kira

AU - Zalis, Maayan

AU - Thaler, Avner

AU - Balash, Yaacov

AU - Hertzel, Shabtai

AU - Gan, Ziv

AU - Kobo, Hila

AU - Hillel, Ariella

AU - Shkedy, Anat

AU - Deik, Andres

AU - Barrett, Matthew James

AU - Cabassa, Jose

AU - Groves, Mark

AU - Hunt, Ann L.

AU - Lubarr, Naomi

AU - Luciano, Marta San

AU - Miravite, Joan

AU - Sachdev, Rivka

AU - Sarva, Harini

AU - Severt, Lawrence

AU - Shanker, Vicki

AU - Swan, Matthew Carrington

AU - Soto-Valencia, Jeannie

AU - Johannes, Brooke

AU - Ortega, Robert

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Background: Ashkenazi Jewish (AJ) LRRK2 carriers are more likely to manifest the postural instability gait difficulty (PIGD) motor phenotype than non-carriers but perform similarly to non-carriers on cognitive screening tests. Objective: To compare the cognitive profiles of AJ with Parkinson's disease (PD) with and without LRRK2 G2019S mutations using a comprehensive neuropsychological battery. Methods: We administered a neuropsychological battery to PD participants in the Michael J. Fox Foundation AJ consortium. Participants (n=236) from Beth Israel Medical Center, NY, Columbia University Medical Center, NY and Tel Aviv Medical Center, Israel included 116 LRRK2 G2019S carriers and 120 non-carriers. Glucocerbrosidase mutation carriers were excluded. We compared performance on each neuropsychological test between carriers and non-carriers. Participants in New York (n=112) were evaluated with the entire battery. Tel Aviv participants (n=124) were evaluated on attention, executive function and psychomotor speed tasks. The association between G2019S mutation status (predictor) and each neuropsychological test (outcome) was assessed using linear regression models adjusted for PIGD motor phenotype, site, sex, age, disease duration, education, Unified Parkinson's Disease Rating Scale (UPDRS) Part III, levodopa equivalent dose, and Geriatric Depression Score (GDS). Results: Carriers had longer disease duration (p

AB - Background: Ashkenazi Jewish (AJ) LRRK2 carriers are more likely to manifest the postural instability gait difficulty (PIGD) motor phenotype than non-carriers but perform similarly to non-carriers on cognitive screening tests. Objective: To compare the cognitive profiles of AJ with Parkinson's disease (PD) with and without LRRK2 G2019S mutations using a comprehensive neuropsychological battery. Methods: We administered a neuropsychological battery to PD participants in the Michael J. Fox Foundation AJ consortium. Participants (n=236) from Beth Israel Medical Center, NY, Columbia University Medical Center, NY and Tel Aviv Medical Center, Israel included 116 LRRK2 G2019S carriers and 120 non-carriers. Glucocerbrosidase mutation carriers were excluded. We compared performance on each neuropsychological test between carriers and non-carriers. Participants in New York (n=112) were evaluated with the entire battery. Tel Aviv participants (n=124) were evaluated on attention, executive function and psychomotor speed tasks. The association between G2019S mutation status (predictor) and each neuropsychological test (outcome) was assessed using linear regression models adjusted for PIGD motor phenotype, site, sex, age, disease duration, education, Unified Parkinson's Disease Rating Scale (UPDRS) Part III, levodopa equivalent dose, and Geriatric Depression Score (GDS). Results: Carriers had longer disease duration (p

KW - Genetics

KW - LRRK2

KW - Neuropsychological tests

KW - Parkinson

UR - http://www.scopus.com/inward/record.url?scp=84921357548&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921357548&partnerID=8YFLogxK

U2 - 10.1016/j.parkreldis.2014.09.033

DO - 10.1016/j.parkreldis.2014.09.033

M3 - Article

VL - 21

SP - 106

EP - 110

JO - Parkinsonism and Related Disorders

JF - Parkinsonism and Related Disorders

SN - 1353-8020

IS - 2

ER -